While several HDAC inhibitors are currently in clinical trials with breast cancer, the SAP30/SIN3 complex may not become a biomarker for guidance of HDAC inhibitor therapy in patients with breast cancer. This evidence concerns the gene HDAC9 and breast carcinoma.